Julie Papanek Grant - Net Worth and Insider Trading
Julie Papanek Grant Net Worth
The estimated net worth of Julie Papanek Grant is at least $124 Million dollars as of 2025-05-11. Julie Papanek Grant is the Director of Protagonist Therapeutics Inc and owns about 2,453,255 shares of Protagonist Therapeutics Inc (PTGX) stock worth over $105 Million. Julie Papanek Grant is also the Director of Day One Biopharmaceuticals Inc and owns about 2,880,761 shares of Day One Biopharmaceuticals Inc (DAWN) stock worth over $19 Million. Details can be seen in Julie Papanek Grant's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Julie Papanek Grant has not made any transactions after 2023-03-01 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Julie Papanek Grant
Julie Papanek Grant Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Julie Papanek Grant owns 2 companies in total, including Protagonist Therapeutics Inc (PTGX) , and Day One Biopharmaceuticals Inc (DAWN) .
Click here to see the complete history of Julie Papanek Grant’s form 4 insider trades.
Insider Ownership Summary of Julie Papanek Grant
| Ticker | Company | Transaction Date | Type of Owner |
|---|---|---|---|
| PTGX | Protagonist Therapeutics Inc | 2016-08-16 | director |
| DAWN | Day One Biopharmaceuticals Inc | 2023-03-01 | director |
Julie Papanek Grant Latest Holdings Summary
Julie Papanek Grant currently owns a total of 2 stocks. Among these stocks, Julie Papanek Grant owns 2,453,255 shares of Protagonist Therapeutics Inc (PTGX) as of August 16, 2016, with a value of $105 Million and a weighting of 85.02%. Julie Papanek Grant also owns 2,880,761 shares of Day One Biopharmaceuticals Inc (DAWN) as of March 1, 2023, with a value of $19 Million and a weighting of 14.98%.
Latest Holdings of Julie Papanek Grant
| Ticker | Company | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| PTGX | Protagonist Therapeutics Inc | 2016-08-16 | 2,453,255 | 42.97 | 105,416,367 |
| DAWN | Day One Biopharmaceuticals Inc | 2023-03-01 | 2,880,761 | 6.45 | 18,580,908 |
Holding Weightings of Julie Papanek Grant
Julie Papanek Grant Form 4 Trading Tracker
According to the SEC Form 4 filings, Julie Papanek Grant has made a total of 0 transactions in Protagonist Therapeutics Inc (PTGX) over the past 5 years. The most-recent trade in Protagonist Therapeutics Inc is the acquisition of 583,333 shares on August 16, 2016, which cost Julie Papanek Grant around $7 Million.
According to the SEC Form 4 filings, Julie Papanek Grant has made a total of 18 transactions in Day One Biopharmaceuticals Inc (DAWN) over the past 5 years, including 1 buys and 17 sells. The most-recent trade in Day One Biopharmaceuticals Inc is the sale of 25,000 shares on March 1, 2023, which brought Julie Papanek Grant around $465,250.
Insider Trading History of Julie Papanek Grant
- 1
Julie Papanek Grant Trading Performance
GuruFocus tracks the stock performance after each of Julie Papanek Grant's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Julie Papanek Grant is 69.86%. GuruFocus also compares Julie Papanek Grant's trading performance to market benchmark return within the same time period. The performance of stocks bought by Julie Papanek Grant within 3 months outperforms 2 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Julie Papanek Grant's insider trading performs compared to the benchmark.
Performance of Julie Papanek Grant
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 16.91 | | | | | |
| Relative Return to S&P 500(%) | 16.4 | | | | | |
Julie Papanek Grant Ownership Network
Ownership Network List of Julie Papanek Grant
Ownership Network Relation of Julie Papanek Grant
Julie Papanek Grant Owned Company Details
What does Protagonist Therapeutics Inc do?
Who are the key executives at Protagonist Therapeutics Inc?
Julie Papanek Grant is the director of Protagonist Therapeutics Inc. Other key executives at Protagonist Therapeutics Inc include Chief Financial Officer Asif Ali , Chief Medical Officer Arturo Md Molina , and director & President and CEO Patel Dinesh V Ph D .
Protagonist Therapeutics Inc (PTGX) Insider Trades Summary
Over the past 18 months, Julie Papanek Grant made no insider transaction in Protagonist Therapeutics Inc (PTGX). Other recent insider transactions involving Protagonist Therapeutics Inc (PTGX) include a net sale of 270,359 shares made by Patel Dinesh V Ph D , a net sale of 66,283 shares made by Asif Ali , and a net sale of 40,975 shares made by William D. Waddill .
In summary, during the past 3 months, insiders sold 66,532 shares of Protagonist Therapeutics Inc (PTGX) in total and bought 0 shares, with a net sale of 66,532 shares. During the past 18 months, 571,042 shares of Protagonist Therapeutics Inc (PTGX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 571,042 shares.
Protagonist Therapeutics Inc (PTGX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Protagonist Therapeutics Inc Insider Transactions
Julie Papanek Grant Mailing Address
Above is the net worth, insider trading, and ownership report for Julie Papanek Grant. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Julie Papanek Grant's mailing address is: Menlo Park Ca 94025.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
